• AM 281 (SKU B6603): Reliable CB1 Antagonist for TBI Research

  2026-07-29

  This article explores how AM 281 (SKU B6603), a potent and selective CB1 cannabinoid receptor antagonist, addresses real-world laboratory challenges in cell viability and neuropharmacology research. Drawing on validated experimental data and current literature, it demonstrates solutions for reproducibility, sensitivity, and protocol optimization. Scenario-driven Q&A blocks provide actionable insights for biomedical researchers seeking reliable tools for cognitive dysfunction and traumatic brain injury models.

• LMO2-LDB1 Complex Drives AML Progression via Transcriptional

  2026-07-29

  This study uncovers the oncogenic role of the LMO2-LDB1 protein complex in promoting acute myeloid leukemia (AML) through transcriptional regulation of apoptosis and proliferation genes. By dissecting the molecular mechanisms and functional consequences of LMO2-LDB1 interactions, the research highlights new avenues for targeted intervention in AML.

• Applied Use-Cases for Alcian Blue & Nuclear Fast Red Stainin

  2026-07-28

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 streamlines mucopolysaccharide and chondrogenic differentiation assays with robust dual-color contrast and simplified workflows. This guide translates bench-tested protocols and troubleshooting insights into actionable steps for reliable, high-contrast tissue staining.

• Pterostilbene Boosts Mitophagy to Delay Dermal Fibroblast Ag

  2026-07-28

  Zhou et al. (2025) present evidence that pterostilbene delays senescence in human dermal fibroblasts by improving mitochondrial quality through enhanced mitophagy. This study clarifies mitochondrial quality control as a promising target for anti-aging interventions in skin research.

• Z-YVAD-FMK: Unlocking Caspase-1 Inhibition for Pyroptosis Re

  2026-07-27

  Explore how Z-YVAD-FMK, a potent caspase-1 inhibitor, enables precise dissection of pyroptosis and inflammasome signaling. Discover unique scientific insights and protocol guidance for apoptosis and cancer research.

• Sulfo-NHS-LC-Biotin: Protocol and QC for Surface Protein Lab

  2026-07-27

  Sulfo-NHS-LC-Biotin enables selective, irreversible biotin labeling of primary amines on proteins, especially useful for cell surface protein biotinylation where aqueous, membrane-impermeable reagents are required. It is not suitable for reversible or intracellular labeling workflows, making it ideal for extracellular detection, purification, or immobilization applications.

• CLK2 Inhibition Overcomes Platinum Resistance in Ovarian Can

  2026-07-26

  This study identifies Cdc2-like kinase 2 (CLK2) as a key driver of platinum resistance in ovarian cancer by enhancing DNA repair via BRCA1 phosphorylation. Targeting CLK2 offers a mechanistically validated approach to restoring platinum sensitivity, with implications for advancing alternative splicing and exon-skipping research.

• Demethyleneberberine: Applied Workflows in Inflammation and

  2026-07-25

  Demethyleneberberine (DMB), a metabolite of berberine, enables robust, mechanism-driven research across inflammation, neurodegeneration, and cancer models. This article details protocol-ready workflows, troubleshooting strategies, and novel insights from recent literature for maximizing DMB’s performance in preclinical and translational settings.

• IAM LC vs LEKC: Advances in Drug–Membrane Partitioning Analy

  2026-07-24

  This study provides a direct comparison between immobilised artificial membrane liquid chromatography (IAM LC) and liposome electrokinetic capillary chromatography (LEKC) for predicting drug partitioning and pulmonary permeability. The findings highlight the differential strengths of each method and offer practical guidance for researchers evaluating drug transport across biological membranes.

• Macrophage EV miR-660 Drives Breast Cancer Metastasis via KL

  2026-07-24

  This study uncovers how microRNA-660, delivered by tumor-associated macrophage extracellular vesicles, accelerates breast cancer progression by targeting KLHL21 and activating NF-κB signaling. The findings highlight a novel intercellular communication axis in the tumor microenvironment, providing mechanistic insight into metastatic regulation.

• WM-8014 for Reproducible KAT6A Inhibition in Cancer Biology

  2026-07-23

  This article explores how WM-8014 (SKU A8779) addresses key experimental challenges in cell cycle arrest, senescence induction, and epigenetic drug target research. Grounded in peer-reviewed evidence and practical workflows, it guides researchers on robust experimental design, protocol optimization, and reliable vendor selection for histone acetyltransferase inhibition.

• Metal-Ion Chelating l-Phe Nanostructures Boost ICB in Tumors

  2026-07-23

  This study introduces metal-ion-chelating L-phenylalanine nanostructures that, in combination with short-term starvation, reprogram the breast tumor microenvironment to overcome immune suppression and enhance the efficacy of immune checkpoint blockade (ICB). The findings reveal a biophysical mechanism for dendritic cell activation and offer a foundation for improved immunotherapy strategies.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Inhibition Wo

  2026-07-22

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor optimized for DMSO-based workflows targeting KIT, PDGFRα, and PDGFRβ. It is particularly useful in research on cancer (notably GIST), mastocytosis, and inflammatory diseases where precise kinase inhibition is required. It should not be used in protocols requiring aqueous or ethanol solubility, nor for broad-spectrum kinase inhibition.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-07-22

  This study employed a structure-based virtual screening approach to identify potent natural product inhibitors of NSP15, a viral endoribonuclease critical to SARS-CoV-2 immune evasion. The discovery of thymopentin and oleuropein as high-affinity, stable NSP15 inhibitors provides new directions for antiviral research and drug development.

• Cl-Amidine Trifluoroacetate: PAD4 Inhibition and Translation

  2026-07-21

  This thought-leadership article explores the strategic deployment of Cl-Amidine (trifluoroacetate salt) as a selective PAD4 inhibitor in translational research. By dissecting mechanistic insights into PAD4-driven epigenetic and immune processes, it bridges foundational evidence from cancer and inflammatory disease models with actionable guidance for researchers. Drawing on recent discoveries in chronic myeloid leukemia and sepsis, the article maps the competitive landscape, protocol strategies, and outlook for PAD4 inhibition as a pivot point in disease modeling and therapeutic innovation.

16311 records 1/1088 page Next 12345 下5页 Last page